8.30Open8.30Pre Close0 Volume1.07K Open Interest12.50Strike Price0.00Turnover472.15%IV-12.90%PremiumJan 17, 2025Expiry Date8.78Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8781Delta0.0709Gamma0.42Leverage Ratio-0.0274Theta-0.0023Rho-0.37Eff Leverage0.0012Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet